Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia
Latest Information Update: 28 Nov 2023
At a glance
- Drugs Phentolamine (Primary) ; Pilocarpine (Primary)
- Indications Presbyopia
- Focus Registrational; Therapeutic Use
- Acronyms VEGA 2
- Sponsors Ocuphire Pharma
- 21 Nov 2023 Status changed from active, no longer recruiting to completed.
- 13 Nov 2023 Primary endpoint (Percent of subjects with 15 letters of improvement in photopic binocular DCNVA and with 5 letters of loss in photopic binocular BCDVA in Nyxol-treated subjects) has been met as per Ocuphire Pharma media release
- 10 Jul 2023 Status changed from recruiting to active, no longer recruiting.